ArticleESMO gastrointestinal oncology2026

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer.

Y Y Janjigian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.